Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Envision Ocular LLC

Neither a doctor nor a teaching hospital

Research payments

$8,291,508

368 payments

Through program year 2025, Envision Ocular LLC is reported as receiving $8,291,508 in research payments, across 368 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $2,727,491 170
2024 Research $2,265,608 55
2023 Research $1,392,288 70
2022 Research $1,906,121 73

Breakdown

Who paid Research payments · program years 2022–2025
  1. Genentech, Inc. $4,735,568 161 payments
  2. Novartis Pharmaceuticals Corporation $2,476,429 6 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $309,386 6 payments
  4. Regeneron Pharmaceuticals, Inc. $196,308 125 payments
  5. EyePoint Pharmaceuticals US, Inc. $170,246 3 payments
  6. Apellis Pharmaceuticals, Inc. $153,262 27 payments
  7. Oyster Point Pharma, Inc. $119,401 11 payments
  8. Kyowa Kirin, Inc. $80,900 23 payments
  9. ANI Pharmaceuticals, Inc. $25,018 1 payment
  10. Roche TCRC, Inc. $14,410 3 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-Of-Concept Study to Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related MacUlar Degeneration $2,476,407 5 payments
  2. Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $1,641,530 20 payments
  3. A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics $820,338 18 payments
  4. Mad to Assess the Safety Tolerability and PK PD in Namd Patients $695,153 23 payments
  5. Faricimab for Under Represented Patients With Dme $667,784 39 payments
  6. A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. $309,386 6 payments
  7. Faricimab Dme Long Term Extension Rhone X $287,695 9 payments
  8. A Phase III Study to Evaluate Faricimab in Patients With Central Retinal Vein Occlusion $196,448 7 payments
  9. A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $196,308 125 payments
  10. A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) $153,615 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record